

QIBA Profile: Quantifying Dopamine Transporters with 123Iodine Labeled Ioflupane in Neurodegenerative Diseases

(Short Title: SPECT dopamine transporters)

Stage: Version 1.1 for Conformance Testing After Responses to Public Comment

**Table of Contents**

[Change Log: 5](#_Toc448590597)

[Open Issues: 6](#_Toc448590598)

[Closed Issues: 6](#_Toc448590599)

[1. Executive Summary 8](#_Toc448590600)

[2. Clinical Context and Claims 9](#_Toc448590601)

[3. Profile Activities 11](#_Toc448590602)

[3.1. Pre-delivery 13](#_Toc448590603)

[3.1.1 Discussion 13](#_Toc448590604)

[3.1.2 Specification 13](#_Toc448590605)

[3.2 Acceptance tests 14](#_Toc448590606)

[3.2.1Discussion 14](#_Toc448590607)

[3.2.2 Specification 14](#_Toc448590608)

[3.3. Periodic QA 14](#_Toc448590609)

[3.3.1 Discussion 15](#_Toc448590610)

[3.3.2 Specification 15](#_Toc448590611)

[3.4. Subject Selection 18](#_Toc448590612)

[3.4.1 Discussion 18](#_Toc448590613)

[3.4.2 Specification 18](#_Toc448590614)

[3.5. Subject Handling 18](#_Toc448590615)

[3.5.1 Discussion 19](#_Toc448590616)

[3.5.2 Specification 19](#_Toc448590617)

[3.6. Image Data Acquisition 19](#_Toc448590618)

[3.6.1 Scanner acquisition mode parameters 19](#_Toc448590619)

[3.6.2 Specification 20](#_Toc448590620)

[3.7. Image Data Reconstruction 24](#_Toc448590622)

[3.7.1 Discussion 24](#_Toc448590623)

[3.7.2 Specification 24](#_Toc448590624)

[3.8. Image QA 24](#_Toc448590625)

[3.8.1 Discussion 24](#_Toc448590626)

[3.8.2 Specification 24](#_Toc448590627)

[3.9. Image Distribution 25](#_Toc448590628)

[3.9.1 Discussion 25](#_Toc448590629)

[3.9.2 Specification 26](#_Toc448590630)

[3.10. Image Analysis 26](#_Toc448590631)

[3.10.1 Discussion 26](#_Toc448590632)

[3.10.2 Specification 28](#_Toc448590633)

[3.11. Image Interpretation 30](#_Toc448590634)

[3.11.1 Discussion 30](#_Toc448590635)

[3.11.2 Specification 31](#_Toc448590636)

[4. Assessment Procedures 32](#_Toc448590637)

[4.1. Assessment Procedure: Voxel Noise 32](#_Toc448590638)

[4.2. Assessment Procedure: <Parameter Y> 33](#_Toc448590639)

[4.3. Assessment Procedure: SPECT Calibration Factor 34](#_Toc448590640)

[4.4 et cetera Phantom Imaging (moved from Section 3) 34](#_Toc448590641)

[References 39](#_Toc448590642)

[Appendices 42](#_Toc448590658)

[Appendix A: Acknowledgements and Attributions 42](#_Toc448590659)

# Change Log:

This table is a best-effort of the authors to summarize significant changes to the Profile.

|  |  |  |
| --- | --- | --- |
| **Date** | **Sections Affected** | **Summary of Change** |
| 2016.01.18 | All | Distribute first rough draft |
| 2016.01.19 | phantoms | To be upgraded on Tuesday telecon |
| 2016.01.22 | 2 (Claims)3 (Requirements) | More sections to be assigned during “big” BC meeting - Mozley |
| 2016.01 | 3.6 Acquisition | Yuni |
| 2016.02.16 | 3.1-3.6moved later | Brian Zimmerman & John Dickson |
| 2016.02.17 |  | Nancy Obuchowski delivers stats for claims |
| 2016.02.19 | all | BIG BC meeting |
| 2016.03.08 | 3.10 | Robert Miyoaka & John Seibyl lead task force meeting to change text |
| 2016.03.15 | 3.10 | Robert Miyoaka delivers revised version |
| 2016.03.14 | 3.9 | Pierre Tervé et al compose the first draft |
| 2016.03.16 | all | line editing & tracked changes clean up (Mozley) detritus |
| 2016.03.16 | 3.6 | CT att. & localization parameters replaced by Image Wisely (Yuni) |
| 2016.03.22 | references | John Seibyl adds first draft |
| 2016.04.14 | 3 & 4 | F2F meeting moves much of Section 3 to 4 |
| 2016.04.14 | 3.1 | Accept Patrick Cella revisions of acceptance testing, etc. |
| 2016.04.15 | 3.1 | Revisions by Johannes of Siemens with copies to Cella of GE |
| 2016.04.15 | 3 | Edits by Eric Frey and start to Recon section |
| 2016.04.26 | all | Edits/additions by John Seibyl |
| 2016.04.28 | all | Clean up by Yuni |
| 2016.05.03 | 3.7 Reconstruction | Eric Frey added Discussion & parts of Table 3.7.2 |
| 2016.05.05 | 3.7.2 | Yuni updated Table 3.7.2 based on May 03 Telecon |
| 2016.05.10 | All | Robert Miyaoka changed ROI to VOI and pixel to voxel |
| 2016.05.10 | 3.10 Image Analysis | Robert Miyaoka incorporated changed discussed during 2016.05.10 conference call |
| 2016.05.17 | 3, 4 | B. Zimmerman incorporated changes discussed during 2016.5.17 conference call |
| 2016.05.20 | 3.10, 4 | J. Dickson suggested a new value (±10%) for variability across qualified imaging systems (3.10) and revised the section on phantom filling |
| 2016.05.20 | Whole Document | Mozley did some trivial line editing |
| 2016.06.07 |  | Eric Frey. Some minor fixes. Made some comments about Open Issues. Added a discussion of calibration and sensitivity in QA section. Moved requirement for attenuation coefficient scaling to QA section. Blended in postfiltering with reconstruction since it depends on the analysis method.  |
| 2016.06.07 | all | Accepted some minor edits made by others |
| 2016.06.07 | Section 4 | Added a couple of paragraphs on Assessment Procedure. Also some cleaning up of Section 4 and refining based on Tuesday June 7 call. |
| 2016.07.05 | 3.10 | Robert Miyaoka added some text referring to the digital reference objects and how they can also be input data for image analysis |
| 2016.07.10 | all | Mozley started deleting instructions from the margins and accepting trivial line edits in preparation for last push to public comment phase |
| 2016.07.12 | 3.10 | Robert Miyaoka made changes in text as discussed in meeting. Added some details about DRO phantom; mentioned the physical phantom; and made slight change to language about number of slices to sum for VOI data analysis. |
| 2016.07.15 | all | Big Biomarker Committee reviewed work product and set deadline for final comments prior to public release |
| 2016.07.19 | Sections 3, 4 | Significant editing done by BZ and JD with regards to performance testing and phantom preparation. Many changes accepted during Phantom and DRO Subcommittee call. |
| 2016.07.29 | 4 | Editing of section 4 and some parts of section 3.6 and 3.7 by Yuni during Aug 2 Tuesday call. |
| 2016.08.12 | 3.8, 4 | Significant edits and reorganization of Section 4 by JD, BZ. To be presented at WebEx on Aug16 |
| 2016.08.17 | 3.8, 3.11, 4 | Revisions following 16-Aug WebEx. Moved table in 3.8 image motion, conspicuous margins etc. into section 3.11 Image interpretation as a prerequisite check prior to image quantification. Change from background region to reference region. Voxel noise CoV value of 15% goes into open issues because size of reference region influences CoV. Other minor text revisions. |
| 2016.08.22 | Reference | References added by Seibyl, other minor edits |
| 2016.09.14 | 3.10 | Accepted changes and made small modification to text for consistency with section 4.2.4. rsm |
| 2016.09.16 | Whole document | Moz Line editing: ran spell checker, changed fonts, accepted trivial edits, accepted major edits that had been vetted (e.g., references) etc. |
| 2016.09.26 | Whole document | Moz: Line editing for consistency. Stylistic word smithing that didn’t change content or address controversy. Made changes to 3.2.2 where comments provoked consensus. |
| 2016.10.01 | Sec. 2 | Revision of claim statements by Dr. Obuchowski & Dr. Jha. |
| 2016.10.01 | Whole document | Moz: General line editing |
| 2016.10.20 | Open issues, claims | Moz: Revisions in response to suggestions from Steering Committee |
| 2016.11.01 | Whole document | Broadcast to public with request for peer review & feedback |
| 2017.03.31 | Whole document | Public comment period closed; begin addressing stakeholder feedback |
| 2017.05.18 | Whole document | YD, JD, RM: Revisions in response to public comments. |
| 2017.06.06 | Whole document | Point-by-point response to all comments complete; draft of Version 1.1 sent back to stakeholders for re-review |
| 2017.06.16 | Whole document | SPECT Biomarker Committee votes to approve Version 1.1 at BIG meeting |
| 2017.06.30 | Whole document | QIBA Coordinating Committee approves Profile Version 1.1 |
| 2017.07.01 | Whole document | Performance Testing begins |

# Open Issues:

The following issues are provided here to capture associated discussion, to focus the attention of reviewers on topics needing feedback, and to track them so they are ultimately resolved. In particular, comments on these issues are highly encouraged during the Public Comment stage. Uncertainty in some scalar values has been highlighted in yellow throughout the text for the purpose of drawing the field’s attention.

|  |
| --- |
| Q. Scalar values surrounding bias are currently uncertain. We note that there are a range of claims in the literature. We expect the reproducibility of estimates of bias to continue varying as new hardware (e.g., CZT detectors, novel pinhole collimator geometry, innovations in in-line CT, etc.), and signal processing algorithms rapidly evolve.A. Proposal to obviate the issue of bias for some users by developing a constrained measurand based on the caudate to putamen ration in some contexts was accepted on 20 May 2016. Groundwork to characterize the bias of most popular cameras has been funded, and is now in progress. Device manufacturers are encouraged to provide their own estimates for an anthropomorphic phantom of the type used in QIBA groundwork. |
| Q. Uncertainty and concern pervades using this profile to distinguish, or “discriminate”, between patients with neurodegenerative diseases and other causes of parkinsonism, such as essential tremor. Would a discrimination claim be acceptable to the community? A. The SPECT Biomarker Committee suggests discriminatory claims have value, and can be adequately trustworthy when used with caution in the context described. However, some residual stakeholder concerns led to discrimination being described as a “use case” in this version of the profile, which appears in the section on cross sectional claims, but is not labeled as a claim per se. |
| Q. The community cannot agree on a method for distinguishing the anterior from the posterior putamen, but the committee notes that there are several software systems that do this. Their groundwork data and analyses are not available for vetting at this time.A. Enterprises claiming conformance based on distinctions between anterior and posterior putamen will need to describe their own methods and present their own evidence of qualification. |

# Addressed Issues:

The following issues have been considered closed by the biomarker committee. They are provided here to forestall discussion of issues that have already been raised and resolved, and to provide a record of the rationale behind the resolution.

|  |
| --- |
| **Q. Is this template open to further revisions?****A.** Yes. This is an iterative process by nature.Submit issues and new suggestions/ideas to the QIBA Process Cmte. |
| **Q. standards: solid (e.g., Cobalt 57, Tellurium-123) or fillable (e.g., solutions of residual 123I ioflupane).**A. Decision has been made to go with fillable striatal phantom for this version. There are plans to develop solid phantoms in the future. |
| **Q. Measurand: specific binding ratio or percent injected dose per gram?**A1. start with striatal binding ratio; launch absolute quant during the next iteration.A2. Decision to delete absolute quant from version 1 implemented on 17 May 2016 |
| **Q. Are the minimal number of counts known?****A.** Groundwork sponsored during Round 6 of NBIB funding successfully characterized some of the relationships between counts and quality. See Section 4.2.1 |

# 1. Executive Summary

Parkinsonism is a major health problem. Distinguishing neurodegenerative causes of parkinsonism from non-degenerative movement disorders that can mimic Parkinson’s disease (PD) has important implications for prognosis and clinical management. The goal of this QIBA Profile is to optimize the performance of Iodine-123 (123I) ioflupane single photon emission computed tomography (SPECT) for quantifying the concentration of regional cerebral dopamine transporters (DaT) in patients with movement disorders.

The **Claims** (Section 2): This profile claims that conformance with its specifications will (1) produce reproducible cross sectional measurements of DaT that can help distinguish normal from abnormal dopamine transporter density, and (2) distinguish true biological change from measurement noise in clinical trials of participants who will be studied longitudinally with 123I-ioflupane. Both claims are founded on observations that neurodegenerative disorders, such as idiopathic PD and Diffuse Lewy Body Dementia (DLBD), are associated with dopaminergic neuronal degeneration, which can be particularly pronounced in the substantia nigra. The degeneration of the axonal projections from the substania nigra to the basal ganglia is manifested as a loss of DaT activity. In most clinical imaging contexts where the question is about a neurodegenerative disorder, the loss is first observed in the most posterior aspect of the putamen, and then seems to march anteriorly, with left and right sides showing asymmetric changes. As a result, quantifying DaT can distinguish normal and abnormal states.

The **Activities** (Section 3) describe what needs to be done to make measurements that reliably distinguish patients from controls with confidence. Requirements are placed on the **Actors** who participate in those activities as necessary to achieve the Claim.

**The Assessment Procedures** (Section 4) for evaluating specific requirements are defined as needed. This QIBA Profile, “Quantifying Dopamine Transporters with 123Iodine Labeled Ioflupane in Neurodegenerative Disease”, addresses quantitative SPECT imaging, which is often used as a diagnostic, as well as a longitudinal biomarker of disease progression or response to treatment. It places requirements on Acquisition Devices, Technologists, Radiologists, Reconstruction Software and Image Analysis Tools involved in Subject Handling, Image Data Acquisition, Image Data Reconstruction, Image QA and Image Analysis.

The requirements are focused on achieving sufficient accuracy and avoiding unnecessary variability of the DaT measurements to distinguish neurodegenerative causes of parkinsonism from non-degenerative causes.

The clinical performance target is to achieve a 95% confidence interval for the striatal binding ratio with both a reproducibility and a repeatability of +/- 15%.

This document is intended to help clinicians basing decisions on this biomarker, imaging staff generating this biomarker, vendor staff developing related products, purchasers of such products, and investigators designing trials with imaging endpoints.

Note that this document only states requirements to achieve the claim, not “requirements on standard of care”. Conformance to this Profile is secondary to properly caring for the patient.

This QIBA Profile, and others like it addressing CT, MRI, PET and ultrasound can be found at [www.qibawiki.rsna.org](http://www.qibawiki.rsna.org) .

# 2. Clinical Context and Claims

Clinical Context

Parkinson’s disease (PD) and Diffuse Lewy Body Dementia (DLBD) are major health problems. The prevalences are increasing as the population ages. Onset can be insidious, which can make the diagnosis challenging on clinical grounds alone. A number of radiopharmaceuticals that can quantify several different components of the pre-synaptic dopamine system have been shown to help distinguish, or “discriminate”, between neurodegenerative causes, such as idiopathic PD, and movement disorders like essential tremor that mimic it. This profile focuses on a marketed radiopharmaceutical for this use, Iodine-123 (123I) labeled ioflupane (methyl (1R,2S,3S,5S)- 3-(4-iodophenyl)- 8-(3-fluoropropyl)- 8-azabicyclo[3.2.1]octane- 2-carboxylate).

**Conformance to this Profile by all relevant staff and equipment supports the following claim(s):**

**Claim 1: Cross sectional.**

**Claim 1a. Calibration.** For a measured specific binding ratio (SBR) of Y, a 95% confidence interval\* for the true putamen SBR is $Y \pm 1.96 ×0.08 ×Y$. For example, if a patient’s measurement of SBR=4 (after the correction for any known bias (see below), then the 95% CI for the true SBR is (4-0.63) to (4+0.63), or [3.33 to 4.63].

**\***The CI is computed from an estimate of the within-subject coefficient of variation.

The assessments of Section 4 need to be performed to verify that the system meets the above total error (< 8%) requirements, which includes assessments of actors’ measurement bias and precision. The above claim assumes that any known bias has already been corrected. For example, if an actor knows that their SBR measurements were consistently 20% too low, then they should logically adjust all of their SBR measurements.

**Claim 1b: Cross sectional.** For a measured caudate:putamen uptake ratio of Y, a 95% confidence interval for the true uptake ratio is $Y \pm 1.96 ×0.08×Y$. For example, if a patient’s measurement of caudate:putamen ratio is 2.5:1 then the 95% CI for the true caudate:putamen ratio is (2.5-0.39) to (2.5+0.39) or [2.11 to 2.89].

**\***The CI is computed from an estimate of the within-subject coefficient of variation.

This claim does not mandatorily require the bias to be corrected for. A major contributor to the bias is a partial volume effect, which depends on the volume of the tissue being sampled. Since the caudate and putamen volumes are similar, the partial volume effects, and hence most of the bias, will cancel out. Of course, it would be ideal if the bias were to be corrected.

**Statement of Use: Cross Sectional Discrimination. Note: This statement of use is proffered with caution on an experimental basis. QIBA encourages all stakeholders to comment. Data supporting or refuting this use are particularly welcome.**

The ability of measurements made in conformance with this profile to discriminate between relevant groups holds when assessing patients during their initial presentations of parkinsonian symptoms, if, but only if, the requirements for quantitative DAT scanning defined in this Profile are met, and the constraints around the clinical context described in this section are valid. If the measurements conform to the requirements of this profile, then measurements of SBR in the posterior putamen that are either (a) 50% or less than the value in aged-matched controls, or (b) 80% or less than the value in the whole striatum are diagnostic for a neurodegenerative cause of the symptoms with a sensitivity of at least 85% and specificity of at least 80%,\* provided none of the contextual caveats described below are violated.

\*These sensitivity and specificity values represent lower 95% confidence bounds.

**Claim 2: Longitudinal Changes Within Subjects**

Claim 2a: Longitudinal detection of change. A measured change in SBR of ∆% indicates that a true change has occurred with 95% confidence if ∆ is larger than 20%\*.

\* 20% is the estimated repeatability coefficient (RC).

Claim 2b: Amount of change. If $Y\_{1}$ and $Y\_{2}$ are the SBR measurements at the two time points, a 95% confidence interval\* for the true change is

$$Y\_{2}-Y\_{1}\pm 1.96 ×\sqrt{(Y\_{1}×0.072)^{2}+\left(Y\_{2}×0.072\right)^{2}}$$

\* 0.072 is the estimated coefficient of variation from an analysis of the literature.

Note: This claim assumes that the bias at both the time points was the same, and thus cancels out.

**Caveats of Context. These claims hold when:**

* Clinical evaluation finds no other cause of parkinsonism, such as recent exposure to known toxins that can present with movement disorders, such as MPTP
* Anatomical imaging, such as magnetic resonance imaging (MRI), has already ruled out other causes of parkinsonism, such as stroke;
* The patient has not been taking drugs or nutritional supplements that can transiently influence the measurements, such as dopamine transporter antagonists
* The patient does not have a deformity or condition that prevents proper positioning in the scanner, such as a severe kyphosis;
* The patient can tolerate the imaging procedures well enough to prevent motion from confounding the acquisition;
* The administration of the radiopharmaceutical is not confounded by infiltration of the dose;
* And other such conditions, which, in the opinion of the professional staff, confound the examination.

**Discussion**

The primary measurand, or outcome measure, is the specific binding ratio (SBR) obtained in the striatum. The measurand is usually divided into separate values for the caudate, anterior putamen, and posterior putamen. While research studies sometimes include the SBR for other structures, such as the substantia nigra pars compacta, the thalamus, amygdala, hippocampus, and cortical gray matter, these regions are beyond the scope of this profile.

The SBR is defined as the count density in a striatal volume of interest (VOI) minus the count density in in a reference region divided by the count density in the reference region, which is often expressed in an equivalent form as the count density in a striatal VOI divided by a count density in a reference region VOI minus 1, and is roughly equivalent to the binding potential (BPnd) using a reference region as estimate of non-displaceable uptake in basal ganglia.

The reference region is ideally the cerebellum, as it contains no known dopaminergic proteins or messenger RNA for these proteins. Acceptable alternatives include the occipital cortex, particularly when the axial field of view is limited.

An alternative outcome measure is the fraction of the injected dose per unit volume in a VOI expressed in units of kBq/mL. This measure is an estimate of transporter number, rather than transporter density. And, it might be an ideal outcome measure in some settings. However, this profile does not mandate absolute quantification.

These claims are based on estimates of the within-subjects coefficient of variation (wCV) for SBRs in the basal ganglia. In the claim statement, the CI is expressed as Y ± 1.96 × Y × wCV. The claim assumes that the wCV is constant for each component of the basal ganglia (e.g., head of caudate and anterior putamen) in the specified size range, and that there is negligible bias in the measurements (i.e., bias after all corrections is < 15%). For estimating the critical % change, the % Repeatability Coefficient (%RC) is used: 2.77 × wCV × 100.

The +/- 15% boundaries can be thought of as “error bars” or “noise” around the measurement of SBR change. If an operator measures change within this range, it cannot be certain that there has really been a change. However, if a SBR changes beyond these limits, then an observer can be 95% confident there has been a true change in the SBR, and the perceived change is not just measurement variability. Note that this does not address the biological significance of the change, just the likelihood that the measured change is real.

Clinical interpretation with respect to the magnitude of true change:
The magnitude of the true change is defined by the measured change and the error bars (+/- 15%). If an operator measures the SBR to be 3.0 at baseline and 1.5 at follow-up, then the measured change is a 50% decrease in SBR (i.e., 100x(3.0 – 1.5)/3.0). The 95% confidence interval for the true change in SBR is is$\left(1.5-3.0\right)\pm 1.96\sqrt{(1.5×0.077)^{2}+(3.0×0.077)^{2}}$, or [-2.01, -0.99], which represents a 33% to 67% decrease in SBR.

Clinical interpretation with respect to progression or response:
A decrease in SBR that exceeds the lower bound of the confidence interval indicates there is a 95% probability of disease progression. An increase in SBR that exceeds the upper bound has a 95% chance of representing a true biological change in the concentration of DaT. The medical implications of changes that are greater than the bounds of the confidence interval are beyond the scope of this profile.

While the cross sectional power of discrimination between patients with dopaminergic neurodegenerative diseases and patients without neurodegenerative diseases described by Claim 1 has been informed by an extensive review of the literature and expert consensus, it has not yet been fully substantiated by studies that strictly conform to the specifications given here. The expectation is that during field testing, data on actual performance will be collected, and any appropriate changes that are indicated will be made to the claim or the details of the Profile. At that point, this caveat may be removed, refined, or re-stated.

# 3. Profile Activities

The Profile is documented in terms of “Actors” performing “Activities”. Equipment, software, staff or sites may claim conformance to this Profile as one or more of the “Actors” in the following table.

Conformant Actors shall support the listed Activities by conforming to all requirements in the referenced Section.

Section 3 Table 1: Actors and Required Activities

|  |  |  |
| --- | --- | --- |
| **Actor** | **Activity** | **Section** |
| Acquisition Device | Pre-delivery | 3.1. |
| Acceptance tests | 3.2 |
| Periodic QA/QC | 3.3 |
| Clinician | Subject Selection | 3.4 |
| Technologist | Subject Handling | 3.5. |
| Image Data Acquisition | 3.6. |
| Image Data Reconstruction | 3.7. |
| Image QA | 3.8. |
| Image Distribution | 3.9. |
| Reconstruction Software | Image Data Reconstruction | 3.7. |
| Image Analysis Tool | Image Analysis | 3.10. |

The requirements in this Profile do not codify a Standard of Care; they only provide guidance intended to achieve the stated Claim. Failing to conform to a “shall” declaration in this Profile could be a protocol deviation. Although deviations could invalidate the Profile Claim, such deviations may be reasonable and unavoidable, and the radiologist or supervising physician is expected to do so when required by the best interest of the patient or research subject. How study sponsors and others decide to handle deviations for their own purposes is entirely up to them.

## 3.1. Pre-delivery

This activity describes calibrations, phantom imaging, performance assessments or validations prior to delivery of SPECT imaging equipment to a site (e.g. performed at the factory) that are necessary to reliably meet the Profile Claim.

### 3.1.1 Discussion

Gamma cameras, radionuclide calibrators and computer workstations must have passed manufacturer release testing and need to be under a schedule of periodic QA and maintenance as described in section 3.3. In order to be compliant with this Profile, the gamma camera should be held to the same standard whether it is a mobile unit or a fixed installation; a mobile gamma camera may require additional calibration to achieve proper performance. The selection and consistent use of appropriate collimators as well as an off-the-bed head holder is necessary to achieve the spatial resolution of the striata required to minimize variability in measurements.

The DICOM format used by the gamma camera and/or processing workstation should meet the Conformance Statement written by manufacturer of each system. SPECT raw and reconstructed data shall be encoded in the DICOM Nuclear Medicine Image Storage SOP Class with additional parameters in public DICOM fields. Any CT data (used for image correction) should be encoded in CT or Enhanced CT Image Storage SOP Class. DICOM data shall be transferred using the DICOM Part 8 network protocol or as offline DICOM Part 10 files for media storage including CDs and DVDs. They shall be transferred without any form of lossy compression.

### 3.1.2 Specification

| **Parameter** | **Actor** | **Requirement** |
| --- | --- | --- |
| Release Testing | Manufacturer | The gamma camera (and any replacements parts) must pass all manufacturing in-process and release testing criteria |
| Non-OEM parts supplier | All parts and accessories must meet or exceed OEM specifications and pass all release testing criteria |
| DICOM format | Manufacturer | Shall meet the Conformance Statement written by manufacturer of each system |
| Computer workstations | Vendor | All workstations used to process images must be validated, able to support the image file type generated by the gamma camera and able to perform the image reconstruction and analysis requirements detailed in Sections 3.7 and 3.10. |
| Camera System | Owned by imaging center; placed by technologist | A camera system should be used that meets the requirements detailed under Image Data Acquisition in Section 3.6. This includes specific requirements for the collimator, projection bin (pixel) size, head-holder, etc. |

### 3.2 INSTALLATION AND Acceptance tests

## 3.2.1 Discussion

Acceptance tests must be performed on systems when they are installed in order to 1) ensure that they meet the performance criteria set forth in the purchasing process, and 2) establish a baseline for evaluation of performance over time. Thereafter, the performance tests described in Section 3.3 should be performed at the interval prescribed, or after any major repair.

A number of documents (for example, see those produced by the ACR and the IAEA,) give specific guidance as to how to conduct these tests.

A qualified medical physicist should perform the tests. Alternatively, the tests may be performed by properly trained individuals approved by the medical physicist. The test results must be reviewed by the qualified medical physicist and properly documented.

### 3.2.2 Specification

| **Parameter** | **Actor** | **Requirement** |
| --- | --- | --- |
| Acceptance tests | Physicist or other trained, qualified personnel | Perform recommended tests at prescribed intervals. |
| Scanner | Must pass initial acceptance tests and perform within prescribed parameters for duration of study. |

## 3.3. Periodic QA

This activity describes calibrations, phantom imaging, performance assessments or validations performed periodically at the site, but not directly associated with a specific subject, that are necessary to reliably meet the Profile Claim.

### 3.3.1 Discussion

A number of documents from several authoritative bodies (e.g., ACR, IAEA, AAPM, NEMA, IPEM, IEC) have been produced that give specific guidance as to how to conduct the tests described below. The list represents a minimum of set of performance measures that should be monitored on a regular basis. Manufacturers’ recommendations and institutional policy may require additional tests or that they be performed at shorter intervals.

A qualified medical physicist should perform these tests. Alternatively, the tests may be performed by properly trained individuals, such as a nuclear medicine technologist, who has been authorized by a supervising medical physicist. The test results must be reviewed by the qualified medical physicist and properly documented.

Note that some specifications that follow come from IAEA Human Health Series 6.

### 3.3.2 Specification

| **Parameter** | **Actor** | **Requirement** |
| --- | --- | --- |

|  |  |  |
| --- | --- | --- |
| Planar Uniformity | Imaging Site | Uniformity of response to a uniform flux of radiation from an I-123 point source shall be measured intrinsically every quarter. On a daily basis planar uniformity with collimators used for I-123 imaging shall be performed using a Tc-99m or Co-57 flood source.. |

|  |  |  |
| --- | --- | --- |
| System Spatial Resolution | Physicist | Tests the resolution of the system in terms of the FWHM of its point spread function. Test shall be conducted semiannually with the collimators routinely used with 123I ioflupane studies. The result of the test shall be less than 8 mm at 10 cm measured using a Tc-99m source. |
| Verification of Center-of-Rotation (COR) | Physicist | Tests the COR offset, alignment of camera Y-axis, and head tilt with respect to the scanner center of rotation. Mean value of the COR offset should not exceed1/2 pixel (typically 2 mm) when measured at the center and edges of the FOV. Position of Y=0 axis and the Y gain shall be the same for all heads in a multi-head system. |
| Photon Energy Analyzer | Physicist | The accuracy of the photon energy analyzer shall be within manufacturer specifications. Verifying this is typically part of daily QC. |
| CT Attenuation map registration | Medical physicist | Shall confirm that the attenuation maps are registered to the SPECT images within the manufacturer specifications. This is typically performed using manufacturer-provided phantoms and procedures. |

## 3.4. Subject Selection

This activity describes criteria and procedures related to the selection of appropriate imaging subjects that are necessary to reliably meet the Profile Claim.

### 3.4.1 Discussion

The study is contraindicated in patients with allergies or hypersensitivity reactions to ioflupane, the excipients in the formulation, or iodine, as about 120 mg of Iodine in the form of potassium iodide should be administered by mouth 0.5-to-2 hours prior to the intravenous administration of the 123I ioflupane formulation to minimize thyroid exposure to any free I-123.

A urine or serum pregnancy test should be performed prior to the procedure in women of childbearing potential. Radiation exposure makes the procedures relatively contraindicated in subjects who are pregnant. Subjects who are breast-feeding at the time of the examination are advised to stop and discard all breast milk for about one week, after which they may resume.

The study is not approved by health authorities for use in children who might have juvenile forms of Parkinson’s disease. While it is known that the product, or similar products, have been approved for research studies in children, this profile is limited to adults with typical basal ganglia size and morphology.

The study is indicated in patients who present with signs and symptoms that are consistent with, but not definitively diagnostic of, Parkinson’s disease (PD), and sometimes for confirming a presynaptic dopamine deficit in patients who are entering a clinical trial. Its U.S. regulatory approval is limited to use as a “visual adjunct imaging agent to aid in the differentiation between essential tremor and parkinsonian syndromes.” Parkinsonian syndromes include Idiopathic Parkinson’s disease (PD), multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and other conditions. Ioflupane is not qualified by national regulatory authorities to distinguish among these conditions.

### 3.4.2 Specification

| **Parameter** | **Actor** | **Requirement** |
| --- | --- | --- |
| Subject Selection | Referring health care provider | For the cross sectional claim, shall establish a differential diagnosis that includes Parkinson’s disease versus other causes of parkinsonism, such as essential tremor. |
| For the longitudinal claim, shall refer eligible subjects |
| Health care provider (nurse, physician, or technologist) | Shall take a history of allergies to iodine;Shall perform a pregnancy test in women of childbearing potential |

## 3.5. Subject Handling

This activity describes details of handling imaging subjects that are necessary to reliably meet the Profile Claim, specifically with regard to preparation, injection, SPECT scan acquisition, follow up instructions, and other logistics occurring on the scanning day.

### 3.5.1 Discussion

All procedures should conform to good clinical practices regarding the provision of information to the patient about the risks, benefits, logistics, and reasonable expectations concerning the imaging activities.

No special preparation is required of the patient regarding diet or fasting prior to the procedure. On the scan day the patient should be questioned regarding iodine allergies prior to the administration of nonradioactive potassium iodide. Additional queries should be made about any thyroid disease or surgeries. If the patient has had a thyroid ablative procedure, complete thyroidectomy or otherwise receives exogenous thyroid hormone replacement, it may not be necessary to perform thyroid blockade. Nonradioactive potassium iodide (100-120 mg) is provided by mouth 30-60 min before anticipated injection of ioflupane. Uptake of the potassium iodide is rapid with some absorption through the gastric mucosa. It is common for patients to describe metallic taste following administration of the thyroid blockade. For patients with iodine allergies potassium perchlorate (400-1000 mg) p.o. has been used, or alternatively, no blockade is performed. Note the low mass dose of iodine contained in radioactive ioflupane does not trigger hypersensitivity reactions in patients with iodine allergies.

Preparation for ioflupane injection involves establishing an intravenous line, usually with the small gauge needle or catheter and confirming patency. Injection of 3-5 mCi of I-123 ioflupane is performed as a bonus over 5 to 20 seconds followed by saline flush of at least 20 mL. There are no specific product guidelines for altering the dose in the context of renal or hepatic impairment. It is not necessary to maintain the patient in a special environment to minimize sensory stimulation during the brain uptake phase. Imaging commences 4 h ± 15 min post injection when a secular equilibrium of washout from the basal ganglia and reference region has occurred. Imaging earlier than four hours underestimates specific binding ratios in some individuals.

 After 3.5 hours following the ioflupane injection the patient is invited to empty their bladder then positioned in the camera. For most SPECT systems a head holder is required to allow the imaging heads to come within a maximum 15 cm radius. It is important that the patient be comfortable from the outset as they will be in the camera for 30 to 45 minutes. Stress on the lumbar spine may be reduced by providing support under the patient’s knees. The head may be gently restrained within the head holder to minimize movement. In addition, instructions highlighting the importance of remaining still should be given several times. During the scan acquisition there should be a low level of stimulation in the room (lights dim, no conversational banter, etc.) to minimize motion.

### 3.5.2 Specification

| **Parameter** | **Actor** | **Requirement** |
| --- | --- | --- |
| Pre-injection | Nuclear pharmacy | Shall provide a system that is capable of receiving, dispensing and administering non-radioactive potassium iodide and 123I ioflupane. |
| Health care provider (nurse, physician, or technologist) | Shall perform a formal “time out” identification procedure; |
| Shall administer about 120 mg of Iodine in the form of Lugol’s solution or supersaturated potassium iodide (SSKI) at least 60 minutes prior to administration of ioflupane, and monitor subjects for adverse events and allergic reactions , such as nausea, vomiting, stomach ache, diarrhea, metallic taste in the mouth, fever, headache, runny nose, or sneezing. |
| Shall establish an intravenous line and prove its patency by showing the rate of a saline drip can be easily altered with an inclined roller. |
| Post-injection | Technologist | Shall ensure the subject voids prior to placement on the table |
| Shall place the subject on the table in such a way that maximizes comfort, minimizes the risk of motion, and positions the basal ganglia as close to the center of the field of view as feasible. |
| Shall select the proper acquisition protocol of 123I ioflupane |
| Shall begin image acquisition at 4 hours +/- 15 minutes post intravenous administration of ioflupane |

## 3.6. Image Data Acquisition

This activity describes details of the data acquisition process that are necessary to reliably meet the Profile Claim.

### 3.6.1 Scanner acquisition mode parameters

We define acquisition mode parameters as those that are specified by the Technologist at the start of the actual SPECT/CT scan. These parameters do not include aspects of the acquisition that occur earlier (e.g., injected activity) or later (e.g., reconstruction parameters) in the overall scan process.

***SPECT Acquisition***

The SPECT acquisition is performed on a properly calibrated SPECT/CT or stand-alone SPECT system with at least two imaging heads fitted with collimators as described in the specifications below. Single headed SPECT systems are not recommended**.** Parallel-beam and fan beam collimators with manufacturer specified (or measured according to NEMA standards) planar system resolution of < 8 mm FWHM (in ‘air’ at 10 cm distance) typically meets the resolution requirement in the table below. These are typically referred to as Low Energy High Resolution (LEHR), Low Energy Ultra-High Resolution (LEUHR) collimators. Some (typical low-energy) collimators allow too much septal penetration of the high-energy emissions I– 123, resulting in ring artifacts that may affect quantitation. ME collimators, which reduce septal penetration, may be insufficient in terms of the resolution requirement. If available, collimators designed specifically for 123I brain SPECT should be used.

Once the patient is placed on the imaging table it is important to have the radius of the rotation as small as possible. This may be particularly challenging in patients with degenerative spine disease or other orthopedic problems affecting posture. The acquisition is adequately performed in step and shoot mode with angular sampling every 3 degrees collecting photopeak counts (159 keV +/- 10%) into a 128 x 128 matrix. Acquisitions are obtained for a minimum of 1.5 million counts. Total time to collect at least 1.5 million counts can be calculated by viewing the count rate in the anterior view. Time per view is total time divided by number of projections.

There are no data that support a rationale for variable SPECT acquisition mode parameters, specifically the acquisition time depending on subject weight and or amount of injected I-123. The acquisition can also be performed as a dynamic SPECT (for example, six 5 minute frames) to better assess motion. Only those frames where significant motion is not evident are summed for the reconstruction.

### 3.6.2 Specification

| **Parameter** | **Actor** | **Requirement** | **DICOM Tag** |
| --- | --- | --- | --- |
| Imaging device | imaging center and its derivatives standard operating procedures | The acquisition device shall be selected to produce comparable results regardless of the scanner make and model. **Camera:** Multi detector SPECT or SPECT/CT cameras shall be used.**Collimator:** A collimator that provides planar system resolution of < 8 mm FWHM (in ‘air’ at 10 cm distance) for Tc-99m shall be used.Head Holder: An off-the-bed head holder (with appropriate cushioning) to achieve an acquisition radius of 12-15cm must be used.  |  |
| Technologist | Shall be certified by local authorities to operate the instrument in compliance with this profile. |  |

| **Parameter** | **Actor** | **Requirement** | **DICOM Tag** |
| --- | --- | --- | --- |
| SPECT Acquisition mode | Imaging center and its applicable standard operating procedures | The key SPECT acquisition mode parameters shall be specified in a manner that is expected to produce comparable results regardless of the scanner make and model. The key parameters are:**Rotational radius**: shall be fixed at 11 – 15 cm (circular orbit) or smallest possible. An off the table head rest is usually needed to achieve this.**Matrix and pixel size**: A matrix size and zoom factor that gives a pixel size of one-third to one-half the expected spatial resolution shall be used. Typically, a 128 x 128 matrix and pixel size of no larger than 4 mm.**Angular sampling:** 360 degree coverage of the head with angular sampling of not less than 120 views shall be used (<= 3 degree increments). Step-and-shoot is typically used, but continuous mode can be used to provide shorter total scan time.**Total counts:** The scan time shall be adjusted to obtain > 1.5 million total counts detected in the photopeak window. Typically, this requires a 25 – 45 min scan.**Energy windows:** The photopeak window shall be set at 159 keV +- 10% (143 – 175 keV) or as recommended by the system manufacturer. If triple energy-window (TEW) based scatter correction is to be used, two additional narrow windows (typically 7%) adjacent to the photopeak or as recommended by the system manufacturer shall be used.  |  |
| Technologist | The technologist shall set up the acquisition, acquire the data, and store the data. |  |

***CT Acquisition***

## For the CT component of the SPECT/CT scan, this Profile only addresses the aspects related to the quantitative accuracy of the SPECT image. The focus is on attenuation correction and anatomical localization only. This profile does not describe a diagnostic CT scan. When CT is used for attenuation correction only, the CT can be performed with 5 – 10 mAs. When used for anatomic localization, the CT can be performed with 30 – 60 mAs (with 110-130 kVp, pitch 0.8-1.5). The CT acquisition parameters should be selected based on Image Wisely guidelines and availability on the scanner.

| **Parameter** | **Actor** | **Requirement** | **DICOM Tag** |
| --- | --- | --- | --- |
| CT Acquisition mode | Imaging center and its applicable standard operating procedures | The key CT acquisition mode parameters (kVp, mAs, pitch, and collimation) shall be specified in a manner that is expected to produce comparable results regardless of the scanner make and model, and with the lowest radiation doses consistent for the role of the CT scan: correction for attenuation and for localization. The CT acquisition mode shall utilize the protocol that delivers the lowest possible amount of radiation dose to the subject (e.g. a relatively low dose protocol) that retains the quantitative accuracy of corrections for attenuation.  |  |
| Technologist | The key CT acquisition mode parameters (kVp, mAs, pitch, and collimation) shall be set as specified by study protocol and used consistently for all subject scans.  |  |

| **Parameter** | **Actor** | **Requirement** | **DICOM Tag** |
| --- | --- | --- | --- |
| CT Technique: Protocol Design  | Technologist / Physician / Medical Physicist  |  A team comprising a Technologist / Physician / Medical Physicist shall ensure that CT techniques protocols are designed such that dose exposure is the lowest radiation dose necessary to achieve the objective. Protocols defined by Image Gently and Image Wisely should be used where feasible. The protocol shall be recorded and documented.  |  |
| Technologist | The technologist shall ensure that the CT dose conforms to the dose prescribed by the supervising physician or protocol.  |  |

## 3.7. Image Data Reconstruction

This activity describes criteria and procedures related to producing images from the acquired data that are necessary to reliably meet the Profile Claim.

### 3.7.1 Discussion

Reconstruction is performed on the projection data following a quality control check of the sinogram to assess for any motion and potential artifacts. Goal of the reconstruction is to provide a well-delineated basal ganglia, which allows regional sampling of the caudate and putamen. Alterations in dopamine transporter density are asymmetric with regard to the caudate and putamen as well as the left and the right side of the brain. The optimal reconstruction, correction, and filtration method depends on the image analysis method used (see Section 3.10).

Images can be reconstructed using either iterative (e.g., OS-EM or conjugate gradient) or analytic reconstruction methods provided appropriate compensations are included, as described below. Iterative methods are typically preferred as they allow for more accurate and complete compensation.

Reconstructed images must be corrected for attenuation. The attenuation map used in the correction can either be measured with a transmission scan, e.g., x-ray CT (preferred), or estimated from boundaries of the head, (e.g. using ellipses). The attenuation correction can be implemented either using iterative (e.g., OSEM), analytical (e.g., Tretiak-Metz), or approximate (e.g., Chang 0) algorithms. Approximate and analytic attenuation correction methods typically use an estimated map and assume uniform attenuation. The use of measured attenuation maps and iterative reconstruction is preferred. Measured attenuation maps obtained from CT images should have the attenuation values translated so that they are appropriate for 159 keV and be registered to the emission images with an accuracy of better than 2 mm.

Correction for scatter is preferred, and should take into account down scatter from high energy photopeaks. Scatter correction can be implemented using energy-window-based scatter estimates (e.g., the TEW method) or scatter modeling methods (e.g., ESSE [Frey, 1996] or Monte Carlo-based [Dewaraja 2006, Beekman 2002]). For filtered backprojection-based reconstruction the scatter estimate is typically subtracted from the projection data. For iterative reconstruction, the scatter compensation should be incorporated into the reconstruction algorithm in order to obtain the best noise properties.

For the whole striatum VOI image analysis method (see Section 3.10), collimator-detector-response (CDR) compensation, a large number of iterations (typically > 100 image updates for OSEM), and little or no post-reconstruction filtering is recommended in order to reduce partial volume effects. Explicit partial volume compensation may be useful for this the whole striatum VOI method. For the small VOI method, CDR compensation may lead to ringing artifacts that complicate quantification and thus is not recommended. A smaller number of iterations and some post-reconstruction low-pass filtering can be useful to help control noise and its effects on the regional activity estimates.

If pre-or post-reconstruction low-pass filtering is applied to the images it is important that the filter be linear across the count ranges. It is desirable that reconstructed images be saved in such a way as to preserve as much dynamic range (numeric precision) as possible and avoid truncation of voxel values. Storing scale factors needed to convert the images to activity concentration units is encouraged.

A core lab and/or common reconstruction methods will provide lower variability and may offer benefits in certain scenarios[Buchert, et al, 2016]..

### 3.7.2 Specification

| **Parameter** | **Actor** | **Requirement** |
| --- | --- | --- |
| SPECT Image Reconstruction | Study Sponsor and Medical Physicist and imaging center and its applicable standard operating procedures | The key SPECT reconstruction parameters (algorithm, iterations, smoothing, field of view, voxel size) shall be specified in a manner that is expected to produce comparable results regardless of the scanner make and model. The key SPECT image reconstruction parameters shall be specified according to pre-determined harmonization parameters.  |
| Technologist | The key SPECT reconstruction parameters (algorithm, iterations, smoothing, field of view, voxel size) shall be followed and set as specified in order to produce comparable results regardless of the scanner make and model.  |
| SPECT Matrix/Voxel size | Technologist | The Technologist shall perform the image reconstruction such that the matrix, slice thickness, and reconstruction zoom shall yield a voxel size of < 4 mm (same as projection bin size) in all three dimensions, although not necessarily isotropic. The final size shall not be achieved by re-binning, etc., of the reconstructed images.  |
| Correction: Attenuation | Technologist | Uniform or non-uniform attenuation correction shall be included in the reconstruction. For uniform correction a narrow beam attenuation coefficient of 0.148 cm-1 shall be used when scatter correction is included while a broad beam attenuation coefficient of 0.11 cm-1 shall be used when scatter correction is not included.For non-uniform attenuation correction the attenuation map shall be obtained by a transmission measurement or x-ray CT (preferred). |
| Estimated Attenuation Map (if used) | Technologist | Shall be defined so that it conforms to the outline of the head as closely as possible. |
| Correction: Scatter | Technologist | Scatter correction shall be used when possible. TEW or equivalent is recommended. |
| Reconstructed image | Technologist | Shall be reconstructed in such a way as to compensate for attenuation and scatter. Optimal reconstruction depends on the image analysis method used (see Section 3.10).**Whole striatum VOI method**: the reconstruction should be implemented to reduce partial volume effects, e.g., using CDR and partial volume compensation. Controlling voxel-level noise is less important, so post-reconstruction filtering is not recommended, though may be used for visual interpretation.**Small VOI method:** the reconstruction should be implemented to control the effects of voxel-level artifacts such as noise spikes and ringing, including the use of 3-dimensional low-pass post-reconstruction filtering (with 8 – 10 mm FWHM).The reconstructed image should have sufficient spatial resolution to allow reliable independent estimates of the SBR in the Caudate and Putamen.  |
| Stored Reconstructed Image | Camera Manufacturer | Reconstructed images should be stored in such a way as to preserve the image dynamic range. |

## 3.8. Image QA/QC

This activity describes criteria and evaluations of the images that are necessary to reliably meet the Profile Claim.

### 3.8.1 Discussion

Many factors can adversely influence image quality, and degrade quantification. Some of these problems can be inferred from a qualitative assessment of the images by an experienced operator, such as a nuclear radiologist. For example, while advanced Parkinson’s disease can produce globally decreased ioflupane uptake in all structures of the basal ganglia, these findings are more likely to represent an infiltrated dose in patients who are making their initial presentations.

### 3.8.2 Specification

The normative list below is based on the recommendations from several national and international guidance document and should be applied as appropriate.

| **Parameter** | **Actor** | **Specification** |
| --- | --- | --- |
| Phantom tests: Frequency | Imaging Site | Shall perform and document results of all tests no less than quarterly, and always after scanner upgrades, and repairs or recalibration of the gamma camera motions and/or detectors |
| Phantom tests:Planar Uniformity | Imaging Site | Uniformity of response to a uniform flux of radiation from a I-123 point source shall be measured intrinsically every quarter. On a daily basis planar uniformity with collimators used for I-123 imaging should be performed using a Tc-99m or Co-57 source |
| System Spatial Resolution | Physicist | Tests the resolution of the system in terms of the FWHM of its point spread function. Test should be conducted semiannually with the collimators routinely used with 123I ioflupane studies. The result of the test should be less than 8 mm at 10 cm. |
| Phantom tests: transaxial uniformity measurement | Imaging Site | Using a uniform cylinder filled with I-123, obtain a within slice variability of less than 5%. |
| Phantom tests:suitability for basal ganglia imaging | Imaging Site | Using an anthropomorphic phantom with basal ganglia and reference region background compartments filled at a homogeneous striatal ratio of 4.5:1, to distinguish the caudate nuclei and putaminal, and also with a caudate/putamen gradient of 4.5:1 caudate, 2.25:1 putamen to assess systems ability to determine an uptake gradient across the striata. This phantom should also be used to check for adequacy of attenuation correction. |
| Phantom test: | Imaging Site | Voxel noise in the reference region/background compartment. The COV of the volume of interest thus determined should be recorded and should be below 15%.  |
| Phantom test: data acquisition | Imaging Site | Shall acquire according to Section 3.6 |
| Phantom test: data reconstruction | Imaging Site | Shall reconstruct according to Section 3.7 |
| Phantom test: data analysis | Imaging Site  | Shall ensure noise is less than specified above. |

## 3.9. Image Distribution

This activity describes criteria and procedures related to distributing images that are necessary to reliably meet the Profile Claim.

### 3.9.1 Discussion

Discussions of archiving and distributing SPECT data often mention 'raw data'. This is an ambiguous term as it can refer to: scanner raw data (i.e., sinograms) or image raw data. To avoid confusion, the term raw data should not be used without making it clear which form is under discussion.

***Scanner raw data*** include the sinograms as acquired from the SPECT scanner, i.e., a list of planar projection images, one image for each acquired angle and energy window. This is always a single DICOM file containing projections images grouped by acquisition energy window. These projections can be analyzed by the Image Data Reconstruction Software.

***Image raw data*** is the image data exactly as produced by the reconstruction process by the Image Data Reconstruction Software, i.e., a stack of DICOM slices/files constituting a SPECT image volume with no processing other than that occurring during image reconstruction. This is always a stack of DICOM slices/files constituting a SPECT image volume that can be analyzed on one or more of the following: SPECT scanner console, SPECT image display workstation, PACS system, etc.

***Post-processed image data*** are images that have been transformed after reconstruction in some manner, including but not limited to: smoothing, image zoom, rotation/translation, resampling, spatial normalization, interpolation, slice averaging, MIP, etc. This is typically a stack of DICOM slices/files constituting a SPECT image volume that can still be analyzed on one or more of the following: SPECT scanner console, SPECT image display workstation, PACS system, etc.

For distributing and archiving at the local site or imaging core lab (if relevant), the most important data are the reconstructed images, i.e., the image raw data, and post processed image data including averaged images if any. In the unlikely event that the scanner raw data (which should be archived by the local site) is required for later reprocessing; this should be made clear in the protocol. Should scanner raw data be archived, all information needed for proper reconstruction and attenuation correction should be kept in DICOM files.

### 3.9.2 Specification

| **Parameter** | **Actor** | **Requirement** |
| --- | --- | --- |
| Image Distribution | Technologist | The original projections (sinogram) images (scanner raw data), shall always be archived at the local site.The reconstructed SPECT images (image raw data), along with all required corrections, and CT images shall always be archived at the local site.If processed SPECT images are required, they shall be archived as separate secondary datasets. If scanner raw data need to be archived for future reprocessing, this should be defined prospectively in the Protocol. |

## 3.10. Image Analysis

This activity describes criteria and procedures related to producing quantitative measurements from the images that are necessary to reliably meet the Profile Claim.

### 3.10.1 Discussion

The Image Analyst using computer workstation analysis tools shall perform the specified measurements. The main quantitative data analysis task is to determine the Specific Binding Ratios (SBR) of Ioflupane (DaTscan™, GE Healthcare, Arlington Heights, IL) for the right and left caudate and putamen. The derived results are then compared to an age-normalized database to provide a reference for the SBR versus age-matched normals. The profile describes the data analysis methodology.

Quantitative Specific Binding Ratio (SBR) of Ioflupane will be based upon patient SBR and compared to an age normalized database (or striatal phantom or digital reference object as the case may be). Qualified systems will be able to achieve a SBR within a certain range (i.e., ±15% of reference value) for quantitative imaging of I-123 Ioflupane for the basal ganglia phantom (described in this profile). Further, the coefficient of repeatability (RC) should be <15% for repeat studies of VOIs that are the size of the whole striatum. The profile seeks to provide the methodology for data analysis and also for qualification of systems and processing for I-123 Ioflupane data analysis.

Input Data:

The output images from Image Reconstruction are considered the input for Image Analysis. Once stored on the analysis workstation the image data will be processed for region of interest image analysis as described below. The original input data will be maintained as a separate file and will be stored along with the processed data for image analysis. In addition to output images from Image Reconstruction, physical phantom and digital reference object images may also be used as input for Image Analysis to validate the Image Analysis and workstation tools. Two types of digital reference objects will be considered. The first will represent the actual I-123 Ioflupane tracer distribution without any of the effects associated with the data acquisition and image reconstruction process. The second object will be a digital representation of first object including all physical effects and image reconstruction. Both digital reference objects will have known SBR’s that can be used to assess the data analysis tools and workstation. The SBR for one half of the DRO will represent healthy control and the other side a patient with Parkinson’s disease. The true caudate to reference region (background) SBR will be the same for both sides and set to 4.5. The Caudate to reference region SBR after image reconstruction is 2.5. The true SBR for the healthy putamen will be 4.5 and 2.25 for the diseased putamen. The physical phantom will be the commercially available striatal Head Phantom. The caudate, putamen and reference/background regions will be filled with activity concentrations that mimic the digital reference object (i.e., actual tracer distribution).

Methods to be Used:

Uptake in the striatum (i.e., caudate, anterior putamen and posterior putamen) and reference region (e.g., cerebellum or occipital region) is characterized by defining a volume-of-interest (VOI). The measurand is the specific binding ratio and is determined from the following equation:

   (eq 1)

where the reference/background (*backgrnd)VOI* counts are normalized to the same VOI volume as the striatal VOI (i.e., caudate or anterior putamen or posterior putamen).

Volumes of interests will be drawn on preprocessed images as described below.

Two volume of interest analysis strategies are described. The first method is referred to as the Small VOI approach. The second method is referred to as the whole striatum VOI approach.

The small VOI approach is described as follows. On spatial normalized SPECT image volumes the transaxial slice with the highest striatal uptake plus and minus up to two adjacent slices spanning an axial extent of 2 cm or less are averaged to generate a single slice image. VOIs are then placed on the left and right caudate, the left and right putamen, and the occipital cortex (reference tissue), as shown in Figure 3.10.1. It should be clear which values belong to which striatal structures. MRI anatomical images can be used for VOI drawing if they exist. VOIs maybe placed according to VOI template or using semi-automated or automated placement tools. Count densities for each region are extracted and used to calculate specific binding ratios (SBRs) for each of the striatal regions. SBR is calculated as ((target region – reference region)/reference region), as described above in eq 1.

Figure 3.10.1. Illustration of Small VOI placement on summed slice image.

The whole striatum VOI approach is similar to the Small VOI approach but uses larger volumes of interest (VOIs) and does not separate the putamen into two regions. The whole striatum VOI approach is implemented in many commercial software packages. The reconstructed image is spatially normalized to a SPECT template. Volumes of interest sampling most of the right and left caudate and putamen are drawn on the image as illustrated in Figure. 3.10.2. Reference/Background VOIs are drawn on the occipital cortex, as shown. VOIs can be systematically placed or semi-automatically or automatically defined over the caudate nucleus and putamen to assess specific tracer binding and over the occipital cortex to assess non-specific binding. The striatal specific binding ratios are calculated using equation 1.

Figure. 3.10.2. Illustration of Large VOI placement on summed image.

Required characteristics of resulting data:

The specific trial protocol shall prospectively define the SBR parameter that is required for the striatum and the caudate and putamen, specifically. Some studies may also compare different metrics (e.g., right to left asymmetry or caudate to putamen ratio) and will require recording multiple parameters. SBR measures (and the analysis tools used to obtain them, including software version) shall be used consistently across all subjects and across all sequential SBR measurements.

SBR’s are intended as a measure of relative uptake and in that sense, can be regarded as dimensionless (unitless)

It should be clear which values belong to which structures (e.g., the whole striatum, left – right caudate, left – right putamen). This can be done by capturing DICOM coordinates along with the SBR or secondary screen captures of the VOI for identification. It should be reported what reference region was used for normalization (e.g., occipital cortex or cerebellum).

The analysis software should generate a report.

### 3.10.2 Specification

| **Parameter** | **Actor** | **Requirement** |
| --- | --- | --- |
| Specific Binding Ratio | Image Analyst | Analysis WorkstationShall have a suitable monitor of appropriate size and pixel density for diagnostic viewing of medical images. Shall be placed in a room with in room lighting appropriate for image data analysis and interpretation (i.e., a radiology reading room). Shall have appropriate computation power and memory to carryout VOI data analysis. |
| Post processed image for data analysisImage for data analysis shall be reconstructed in accordance with parameters as described in Section 3.7. If needed, image is spatially normalized. If using the Small VOI approach, the transaxial slice with the highest striatal uptake plus and minus up to two adjacent slices spanning an axial extent of 2 cm or less are averaged to generate a single slice image. |
| VOI software analysis toolsUsing analysis workstation tools, volumes of interest are placed on the left and right caudate, the left and right putamen, and the reference tissue. Count densities for each region are extracted to calculate SBRs for each of the striatal regions and for the striatum as a whole. VOIs shall be systematically placed by the image analyst or by the image analysis software.  |
| Certify VOI | Qualified professional | Shall either (1) agree with region boundaries, (2) reject boundaries and return for reprocessing, or (3) make revisions “on the fly” as indicated. |

## 3.11. Image Certification and Interpretation

This activity describes criteria and procedures related to clinically interpreting the measurements and images that are necessary to reliably meet the Profile Claim.

### 3.11.1 Discussion

**In the USA**, under the Centers for Medicare & Medicaid Services’ Medicare Improvements for Patients and Providers Act of 2008 (MIPPA), the American College of Radiology (ACR) is required to validate compliance with accreditation requirements on advanced diagnostic imaging service facilities. Facilities should refer to the tool kit available on the ACR website at the bottom of the Breast MRI, CT, MRI, Nuclear Medicine and PET Accreditation Program pages located at <http://www.acraccreditation.org/modalities/mri>

These documents will help facilities gather and organize information for periodic the site surveys.

Some of the most common items that are not found during a survey are the following:

• Policies for primary source verification, verifying that personnel are not included on the Office of Inspector General’s exclusion list and a consumer complaint notice that gives the patients contact information for the ACR (one can be found on our website at <http://www.acr.org/~/media/ACR/Documents/Accreditation/PatientNotice.pdf> .

• Documentation of initial qualifications, continued education and continued experience for the interpreting physician and medical physicist. Self-documentation is not acceptable.

**In Japan**, the European Union, and other regions, professional health care providers should meet, and maintain, standards set by their local regulatory authorities for the practice of medicine with unsealed radioactive material.

Visual image assessment is performed to assess he adequacy of the acquisition for a quantitative endpoint. Checks for the integrity of the reconstruction include well-defined basal ganglia, nonspecific cortical uptake with sharp boundaries of the cortical edge, and well-defined scalp uptake. Signs of motion include blurring of the boundaries between high uptake areas in the basal ganglia and adjacent regions, e.g. the heads of the caudate may appear too close.

Assessment of the quality of the subsequent quantitative analysis is critical, with particular focus on the accurate anatomic placing of the regions of interest.

### 3.11.2 Specification

| **Parameter** | **Actor** | **Requirement** |
| --- | --- | --- |
| count sufficiency | nuclear medicine specialist or nuclear radiologist | Shall confirm sufficient counts have been acquired to reconstruct the images properly |
| clear, conspicuous margins | Shall confirm the margins are sufficiently conspicuous and have not been degraded by excessive patient motion. |
| Excessive motion | Shall confirm that image quality has not been degraded by excessive patient motion. |
| Proper positioning in FOV | Shall confirm that basal ganglia are in the field of view by assessing where the top of the head is. |
| artifacts | Shall ensure assessment is not confounded by ring artifacts, artifacts related to too large a radius for COR (i.e., should be <15 cm, or edge artifacts |
| Mis-registration of SPECT/CT or discordance of Chang’s | Shall ensure that the attenuation map is visually registered to the CT map within one reconstructed voxel dimension. |

| **Parameter** | **Actor** | **Requirement** |
| --- | --- | --- |
| Place VOI | Technologist or image analysis specialist | For SBR, shall cause to have placed volumes of interest (VOI) on structures of interest and appropriate reference tissue. VOIs include caudate, anterior putamen, and posterior putamen on each side of brain. |
| Calculate measurand | Technologist or image analysis specialist | Shall calculate time-point measurand (SBR or %dose/mL) |
| Certify VOI | Qualified physician | Shall either (1) agree with region boundaries, (2) reject boundaries and return for reprocessing, or (3) make revisions “on the fly” as indicated. |
| Certify measurand | Qualified physician | Shall either (1) agree with region boundaries, (2) reject boundaries and return for reprocessing, or (3) make revisions “on the fly” as indicated. |
| classification | Qualified physician | Claim 1: interpret measurand as consistent with, or not consistent with, Parkinson’s disease.Claim 2: interpret measurand a consistent with a value of X +/- y, where x is the measured value, and y is the confidence interval described in Section 2 under Claim 2Claim 3: interpret the measurand as consistent with, or not diagnostic of, change greater than the Repeatability Coefficient (RC) described above |

# 4. Assessment Procedures

## 4.1. Assessment Procedures: Acceptance Testing

To conform to this Profile, participating staff and equipment (“Actors”) shall support each activity assigned to them.

To support an activity, the actor shall conform to the requirements (indicated by “shall language”) listed in the specifications table of the activity subsection in Section 3.

Although most of the requirements described in Section 3 can be assessed for conformance by direct observation, some of the performance-oriented requirements cannot, in which case the requirement will reference an assessment procedure in a subsection here in Section 4.

Formal claims of conformance by the organization responsible for an Actor shall be in the form of a published QIBA Conformance Statement. Vendors publishing a QIBA Conformance Statement shall provide a set of “Model-specific Parameters” (as shown in Appendix D) describing how their product was configured to achieve conformance. Vendors shall also provide access or describe the characteristics of the test set used for conformance testing.

As discussed in Section 3.2, a number of guidance documents are available that describe the appropriate tests to be performed upon delivery of a new scanner. The procedures in those documents should be followed consistently and the results compared to the passing criteria defined either by the test guidance or the manufacturer.

## 4.2 Image QA/QC

## 4.2.1 Assessment Procedure: Planar Uniformity

## Planar Uniformity (without collimator): At least every quarter, detector response to I-123 should be assessed intrinsically following the guidelines of authoritative bodies such as IAEA, AAPM, NEMA, IPEM, IEC. A flood image can be produced by suspending a small point source above the uncollimated gamma camera at a distance of five times the diameter of the crystal. Image count densities of at least 10,000 counts per pixel should be acquired (about 30 million total counts for a 64x64 matrix). The image should be visually assessed for variations in count density, noting any areas that clearly stand out. In addition, quantitative measurements of uniformity indices (integral uniformity and differential uniformity) defined in the above-mentioned guidelines should be carried out. Values should be recorded and compared with those obtained at acceptance and the action levels established at the time of acceptance testing

System Uniformity (with collimator). Given that I-123 is an expensive product, the consistency of uniformity should be checked daily using either Tc-99m or Co-57 following the guidelines recommended by system manufacturers. For system uniformity measurements a flood source is placed in contact with the collimator face and 10 - 30 million total counts should be acquired. The image should be visually assessed for variations in count density. In addition, quantitative measurements of uniformity indices (such as coefficient of variation, integral uniformity and differential uniformity) should be carried out. Values should be recorded and compared with those obtained at acceptance and the action levels established at the time of acceptance testing.

## 4.2.2 Assessment Procedure: Planar Spatial Resolution

The requirement on spatial resolution can be assessed by following the NEMA guidelines for measuring system spatial resolution without scatter. This test requires a capillary tube with inside diameter < 1 mm and an active filled length of at least 120 mm to be filled with Tc-99m and imaged positioned 100mm from the face of the collimator in air and along the axis of measurement. Details of the measurement can be found in Performance Measures of Gamma Cameras NEMA NU 1-2012. The FWHM of the line spread function shall be measured as outlined in the NEMA document and compared with the requirements of Section 3.6 (FWHM < 8 mm).

## 4.2.3 Assessment Procedure: Center of Rotation

Center of rotation performance can be assessed by following the NEMA guidelines for measuring system alignment of gamma camera tomographic systems. The mean value of the COR offset should not exceed 1/2 pixel (typically 2 mm) when measured at the center and edges of the FOV. Position of Y=0 axis and the Y gain should be the same for all heads in a multi-head system.

## 4.2.4 Assessment Procedure: Tomographic Uniformity

As a SPECT technique, Ioflupane imaging requires correction for photon attenuation within the brain to be accurately quantified. Using either Chang 0 or iterative compensation or estimated or measured attenuation maps, it is important to assess that the correction for attenuation is being applied appropriately. It is also important to assess that center of rotation corrections are fit for purpose. With such potential sources of error, it is important for all trials that transaxial plane uniformity is assessed. This can be achieved by acquiring a high count (~15 million counts) SPECT acquisition of a cylindrical phantom filled with Iodine-123 solution. Following reconstruction with corrections applied for attenuation and possibly scatter, a profile about 3 cm wide should be placed through the centre of rotation of the phantom, and the resulting count distribution visually assessed for the appropriateness of CT or calculated attenuation correction. A correctly applied attenuation correction should yield a flat proflie other than image noise.

The performance of the system with such tests may change following any detector changes or recalibration, and for SPECT after mechanical changes made to the system, and should therefore be checked after such actions have been performed.

## 4.2.5 Suitability for Basal Ganglia Imaging

To qualify the SPECT scanner for clinical practice or for a clinical trial, a phantom imaging procedure is required. For the specific application described in this document, the commercially-available striatal Head Phantom with removal brain shell is to be used for the tests described below. The phantom should be filled such that the activity concentration in the uniform area of the brain shell is approximately 5 kBq/ml (0.135 uCi/ml), similar to the expected average normal tissue concentration at the time of imaging in an average weight (70-80 kg) subject in combination with the intended I-123 ioflupane dosage of up to 185 MBq (5 mCi).

To characterize system performance, two different scenarios should be created within the striatal phantom: one side will represent a healthy subject, while the other will demonstrate dopaminergic degeneration typical of Parkinson’s disease.

Both striatal compartments on the right side of the phantom should be filled with the same concentration representing a true uptake ratio of 4.5:1. Given that the reference/background compartment has a ratio of 5 kBq/ml and on the basis that SBR = (compartment – background) / background, the activity concentration of these striatal compartments will be 27.5 kBq/ml (0.74 uCi/ml). The left striatal compartment will also have a caudate SBR of 4.5:1 and a putamen SBR of 2.25:1. This putaminal ratio of 2.25:1 will require a solution with an activity concentration of 16.25 kBq/ml (0.43uCi/ml). A 1ml aliquot should be taken from each filling solution so that true SBRs can be calculated. Assuming a reference/background compartment volume of 1500 ml, the required concentration can be reached by adding 7.5 MBq (0.20 mCi) of I-123 to this volume. The volume of the right striatum and left caudate is 17.4 ml. Creating 20ml of solution to fill these compartments would require 0.55 MBq (14.9uCi). The left putamen volume is 6 ml. Producing 10ml of filling solution for this compartment would require 0.16 MBq (4.4uCi). Multiple dilutions will often be necessary to reach accurate values for the striatal dilutions given the issues of radionuclide calibrators in this range. All activities should be measured on a dose calibrator undergoing Quality Control as recommended by, e.g., AAPM, IAEA and with accuracy traceability to NIST or equivalent metrology labs.

Phantom measurement should be done to compare measured SBR with the known ‘truth’, which should give a bias of < 50%. Similarly, the measured caudate:putamen ratio should be compared with the true ratio to determine the consistent bias, which should be < 10%. Once these calibrations are performed the system should be tested with test-retest measurements using the striatal phantom with multiple acquisitions as the phantom decays. The repeatability coefficient from these measurements should be within 20%.

Following reconstruction with corrections applied for attenuation and possibly scatter, a profile about 3 cm wide should be placed through the identified uniform region of the brain background. The count distribution should be visually assessed for the appropriateness of the attenuation correction. A correctly applied attenuation correction should yield a flat proflie other than image noise.

The phantom scans and performance evaluation should be performed prior to the start of a trial and repeated during the course of the trial as specified by the individual protocol. Any changes to scanner equipment, either hardware or software, should be immediately reported to the trial sponsor and/or imaging CRO and may result in the need for re-qualification prior to imaging additional trial subjects. In particular, it is strongly recommended that subjects in a longitudinal study be scanned on the same SPECT system with the same software version whenever possible. Moreover, image reconstruction methods and settings used for the phantom study should be equal to those specified in the trial protocol or equal to those routinely applied in the local clinical setting.

## 4.2.6 Assessment Procedure: Voxel Noise in the Reference/Background Compartment

Specific Binding Ratio (SBR) calculations involve the regions of interest in the striata and also a region such as the cerebellum or occipital lobe, which acts as a measure of non-specific tracer binding. Noise levels in the non-specific binding region will therefore have an impact on the uncertainty in SBR.

Image noise levels in this region should be measured using the anthropomorphic striatal phantom of (Section 4.2.4) with a uniform area to assess image ‘noise’ by means of the coefficient of variation (COV). The COV is also known as the relative standard deviation (%RSD), which is expressed as a percentage and is defined as COV = (SD / Mean) x 100, for the voxel values within a specified volume of interest (VOI). The phantom should be scanned using the minimal time per bed specified in the trial protocol or using the routinely applied time per bed in the local clinical setting. Moreover, image reconstruction methods and settings should equal those specified in the trial protocol or equal those routinely applied in the local clinical setting. A volume of interest (VOI) should be positioned entirely within the phantom’s uniform area (the brain compartment), with its size and position chosen to match that used to quantify SBR. The COV of the volume of interest thus determined should be recorded and should be below 15%. If the COV of the voxel values thus determined is above 15%, the acquisition time should be increased accordingly

| **Parameter** | **Entity/Actor** | **Requirement** |
| --- | --- | --- |
| Planar Uniformity QC | Technologist | At least quarterly and following detector changes, calibrations and/or software upgrades the uniformity of detector response to a uniform flux of radiation of Iodine-123 should be assessed.Daily, or at least on the day of a trial subject, the collimated uniformity of the detectors using collimators to be used for Iodine-123 imaging should be assessed using a Tc-99m or Co-57 source.For both measurements, uniformity should be measured and assessed in accordance with local regulatory requirements. |
| SPECT uniformity QC | Technologistor Medical Physicist | At least quarterly and following detector changes, calibrations and/or software upgrades, the SPECT uniformity should be measured using acquisition parameters defined in the clinical protocol trial. |

## 4.2.7 Assessment Procedure: Motion & Artifacts

After acquisition and before reconstruction review of projection data in cine mode and sinograms shall be used for an initial determination of scan quality, patient motion, and artifacts. Cine review of planar images will show up patient motion along the axis of rotation. A horizontal reference line overlying the image can be used to assess motion (‘kissing’ caudate if motion). Sinogram review will reveal transverse patient motion as discontinuities in the sinusoidal form of shapes included within the image.

The acquisition can also be performed as a dynamic SPECT (for example, six 5 minute frames) to better assess motion. After reviewing the sinograms of each rotation only those frames where significant motion is not evident are summed for the reconstruction, excluding projection data with patient motion.

## 4.2.8 Assessment Procedure: Total SPECT Performance (Image Certification and Interpretation)

Image acquisition and processing requirements described in Section 3 shall be assessed for conformance by direct observation of the reconstructed SPECT image corresponding to the anthropomorphic striatal phantom of Section 4.2.4. Image should be of sufficient quality to identify discrete left and right basal ganglia, which have the appearance of a comma shaped object. In addition the head of the caudate should be distinguishable from the tail of the putamen. The appearance of the basal ganglia should be a linear structure (hooked curvilinear similar to a comma with a tail). Improper acquisition and reconstruction parameters will result in a bloated ovoid shape

For a semi-quantitative assessment, the measured SBR for the above striatal phantom shall be compared with the reference value (should be within 15% of the reference value).

In addition, the image analysis software used for SBR determination shall provide a caudate to background value of 2.5 ± 0.375 for the right caudate to background for the DRO.

# References

### **INSTALLATION, Acceptance tests, AND Periodic QA**

American Association of Physicists in Medicine. Rotating Scintillation Camera SPECT Acceptance Testing and Quality Control, Rep. 22, AAPM, New York (1987).

American College of Radiology. Nuclear medicine accreditation program requirements [Internet]. Reston, VA: American College of Radiology; 2012. Available from:

<http://www.acr.org/~/media/ACR/Documents/Accreditation/Nuclear%20Medicine%20PET/Requirements.pdf>

Graham, LS. The AAPM/RSNA Physics Tutorial for Residents: Quality Control for SPECT Systems. Radiographics. 1995 15:1471-1481.

Hines H, Kayayan R, Colsher J, et al. National Electrical Manufacturers Association recommendations for implementing SPECT instrumentation quality control. J Nucl Med 2000;41:383-389.

Institute of Physics and Engineering in Medicine. Quality Assurance in Gamma Camera Systems, Rep. 86, IPEM, New York (2003).

International Electrotechnical Commission. Radionuclide imaging devices - Characteristics and test conditions - Part 2: Single photon emission computed tomographs, 60789-2, IEC, Geneva (1998).

International Electrotechnical Commission. Radionuclide imaging devices - Characteristics and test conditions - Part 2: Single photon emission computed tomographs, Amendment 1, 60789-2-am 1, IEC, Geneva (2004).

International Electrotechnical Commission. Characteristics and test conditions - Part 3: Gamma camera based wholebody imaging systems, 61675-3, IEC, Geneva (1998).

National Electrical Manufacturers Association., Performance Measurements of Scintillation Cameras, National Electrical Manufacturers Association, NU 1-2001, NEMA, Rosslyn, Virginia, USA (2001).

Tossici-Bolt L, Dickson JC, Sera T, de Nijs R, Bagnara MC, Jonsson C, et al. Calibration of gamma camera systems for a multicentre European 123I-FP-CIT SPECT normal database. Eur J Nucl Med Mol Imaging 2011;38(8):1529-40.

### **Subject Selection and Subject Handling**

# Darcourt J, Booij J, Tatsch K, Varrone A, Vander Borght T, Kapucu OL, Någren K, Nobili F, Walker Z, Van Laere K. EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):443-50.

# Djang DS, Janssen MJ, Bohnen N, Booij J, Henderson TA, Herholz K, Minoshima S, Rowe CC, Sabri O, Seibyl J, Van Berckel BN, Wanner M. SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0. J Nucl Med. 2012 Jan;53(1):154-63.

# Datscan Prescribing Information: <http://www3.gehealthcare.com/en/products/categories/nuclear_imaging_agents/datscan>

Walker, Z., E. Moreno, A. Thomas, F. Inglis, N. Tabet, M. Rainer, G. Pizzolato, A. Padovani and T. D. L. B. P. S. G. Da (2015). "Clinical usefulness of dopamine transporter SPECT imaging with 123I-FP-CIT in patients with possible dementia with Lewy bodies: randomised study." Br J Psychiatry **206**(2): 145-152.

Vlaar, A. M., T. de Nijs, A. G. Kessels, F. W. Vreeling, A. Winogrodzka, W. H. Mess, S. C. Tromp, M. J. van Kroonenburgh and W. E. Weber (2008). "Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes." Eur Neurol **59**(5): 258-266.

Tolosa, E., T. V. Borght, E. Moreno and T. C. U. P. S. S. G. Da (2007). "Accuracy of DaTSCAN (123I-Ioflupane) SPECT in diagnosis of patients with clinically uncertain parkinsonism: 2-year follow-up of an open-label study." Mov Disord **22**(16): 2346-2351.

Seifert, K. D. and J. I. Wiener (2013). "The impact of DaTscan on the diagnosis and management of movement disorders: A retrospective study." Am J Neurodegener Dis **2**(1): 29-34.

O'Brien, J. T., W. H. Oertel, I. G. McKeith, D. G. Grosset, Z. Walker, K. Tatsch, E. Tolosa, P. F. Sherwin and I. D. Grachev (2014). "Is ioflupane I123 injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials." BMJ Open **4**(7): e005122.

Menendez-Gonzalez, M., F. Tavares, N. Zeidan, J. M. Salas-Pacheco and O. Arias-Carrion (2014). "Diagnoses behind patients with hard-to-classify tremor and normal DaT-SPECT: a clinical follow up study." Front Aging Neurosci **6**: 56.

Martinez-Valle Torres, M. D., S. J. Ortega Lozano, M. J. Gomez Heredia, T. Amrani Raissouni, E. Ramos Moreno, P. Moya Espinosa and J. M. Jimenez-Hoyuela (2014). "Longitudinal evaluation using FP-CIT in patients with parkinsonism." Neurologia **29**(6): 327-333.

Kupsch, A. R., N. Bajaj, F. Weiland, A. Tartaglione, S. Klutmann, M. Buitendyk, P. Sherwin, A. Tate and I. D. Grachev (2012). "Impact of DaTscan SPECT imaging on clinical management, diagnosis, confidence of diagnosis, quality of life, health resource use and safety in patients with clinically uncertain parkinsonian syndromes: a prospective 1-year follow-up of an open-label controlled study." J Neurol Neurosurg Psychiatry **83**(6): 620-628.

Kupsch, A., N. Bajaj, F. Weiland, A. Tartaglione, S. Klutmann, R. Copp, P. Sherwin, A. Tate and I. D. Grachev (2013). "Changes in clinical management and diagnosis following DaTscan SPECT imaging in patients with clinically uncertain parkinsonian syndromes: a 12-week follow-up study." Neurodegener Dis **11**(1): 22-32.

Hauser, R. A. and D. G. Grosset (2012). "[123I]FP-CIT (DaTscan) SPECT brain imaging in patients with suspected parkinsonian syndromes." J Neuroimaging **22**(3): 225-230.

Gomez-Rio, M., M. M. Caballero, J. M. Saez and A. M. Castellanos (2015). "Diagnosis of Neurodegenerative Diseases: the Clinical Approach." Curr Alzheimer Res.

Gayed, I., U. Joseph, M. Fanous, D. Wan, M. Schiess, W. Ondo and K. S. Won (2015). "The impact of DaTscan in the diagnosis of Parkinson disease." Clin Nucl Med **40**(5): 390-393.

Cummings, J. L., C. Henchcliffe, S. Schaier, T. Simuni, A. Waxman and P. Kemp (2011). "The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration." Brain **134**(Pt 11): 3146-3166.

Cummings, J. L., M. J. Fine, I. D. Grachev, C. R. Jarecke, M. K. Johnson, P. H. Kuo, K. L. Schaecher, J. A. Oberdorf, M. Rezak, D. E. Riley and D. Truong (2014). "Effective and efficient diagnosis of parkinsonism: the role of dopamine transporter SPECT imaging with ioflupane I-123 injection (DaTscan)." Am J Manag Care **20**(5 Suppl): S97-109.

Catafau, A. M., E. Tolosa and T. C. U. P. S. S. G. Da (2004). "Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes." Mov Disord **19**(10): 1175-1182.

Tossici-Bolt L, Hoffmann SM, Kemp PM, Mehta RL, Fleming JS. Quantification of [123I]FP-CIT SPECT brain images: an accurate technique for measurement of the specific binding ratio. Eur J Nucl Med Mol Imaging 2006;33(12):1491-1419.

Koch W, Unterrainer M, Xiong G, Bartenstein P, Diemling M, Varrone A, et al. Extrastriatal binding of [(1)(2)(3)I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls. Eur J Nucl Med Mol Imaging 2014;41(10):1938-1946.

### **Image Data Acquisition and Reconstruction**

Zaknun, J. J., H. Schucktanz and F. Aichner (2007). "Impact of instrumentation on DaTSCAN imaging: how feasible is the concept of cross-systems correction factor?" Q J Nucl Med Mol Imaging **51**(2): 194-203.

Varrone et al. Comparison between a dual-head and a brain-dedicated SPECT system in the measurement of the loss of dopamine transporters with [123I]FP-CIT. Eur J Nucl Med Mol Imaging. 2008 Jul;35(7):1343-9.

Varrone A, Dickson JC, Tossici-Bolt L et al. European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. Eur J Nucl Med Mol Imaging. 2013 Jan;40(2):213-27.

Skanjeti, A., G. Castellano, B. O. Elia, M. Zotta, F. Dazzara, M. Manfredi, A. Galati, S. Grimaldi, M. Balma, R. E. Pellerito and V. Podio (2015). "Multicenter Semiquantitative Evaluation of (123)I-FP-CIT Brain SPECT." J Neuroimaging **25**(6): 1023-1029.

# Rault E et al. Comparison of image quality of different iodine isotopes (I-123, I-124, and I-131). Cancer Biother Radiopharm. 2007 Jun;22(3):423-30.

# Tossici-Bolt L, Dickson JC, Sera T et al. Calibration of gamma camera systems for a multicentre European ¹²³I-FP-CIT SPECT normal database. Eur J Nucl Med Mol Imaging. 2011 Aug;38(8):1529-40.

Rajeevan, N., I. G. Zubal, S. Q. Ramsby, S. S. Zoghbi, J. Seibyl and R. B. Innis (1998). "Significance of nonuniform attenuation correction in quantitative brain SPECT imaging." J Nucl Med **39**(10): 1719-1726.

Lange, C., A. Seese, S. Schwarzenbock, K. Steinhoff, B. Umland-Seidler, B. J. Krause, W. Brenner, O. Sabri, J. Kurth, S. Hesse and R. Buchert (2014). "CT-based attenuation correction in I-123-ioflupane SPECT." PLoS One **9**(9): e108328.

Lange, C., J. Kurth, A. Seese, S. Schwarzenbock, K. Steinhoff, B. Umland-Seidler, B. J. Krause, W. Brenner, O. Sabri, S. Hesse and R. Buchert (2015). "Robust, fully automatic delineation of the head contour by stereotactical normalization for attenuation correction according to Chang in dopamine transporter scintigraphy." Eur Radiol **25**(9): 2709-2717.

Bienkiewicz, M., M. Gorska-Chrzastek, J. Siennicki, A. Gajos, A. Bogucki, A. Mochecka-Thoelke, A. Plachcinska and J. Kusmierek (2008). "Impact of CT based attenuation correction on quantitative assessment of DaTSCAN ((123)I-Ioflupane) imaging in diagnosis of extrapyramidal diseases." Nucl Med Rev Cent East Eur **11**(2): 53-58.

Iida H, Narita Y, Kado H, Kashikura A, Sugawara S, Shoji Y, et al. Effects of scatter and attenuation correction on quantitative assessment of regional cerebral blood flow with SPECT. J Nucl Med 1998;39(1):181-189.

Frey, E.C., Tsui, B.M.W., A new method for modelling the spatially-variant, object dependent scatter response function in SPECT *Record 1996 IEEE Nuclear Science Symp. and Medical Imaging Conf. (Anaheim, CA, 1996)* (Piscataway, NJ:IEEE) pp 1082–6.

Dewaraja, Y.K., Ljungberg, M., Fessler, J.A., 3-D Monte Carlo-based Scatter Compensation in Quantitative I-131 SPECT Reconstruction. IEEE TNS, vol.53(1):181-188, 2006.

Beekman FJ, de Jong WAM, van Geloven S. Efficient fully 3-D iterative SPECT reconstruction with Monte Carlo based scatter compensation. IEEE Trans. Med. Imag. 2002 Aug;21(8):867–877.

### **Image QA/QC, Image Distribution, AND Analysis**

International Atomic Energy Agency (IAEA), IAEA Human Health Series No. 6: Quality Assurance for SPECT Systems, International Atomic Energy Agency, Vienna (2009).

Pierce LA, Elston BF, Clunie DA, Nelson D, and Kinahan PE. A Digital Reference Object to Analyze Calculation Accuracy of PET Standardized Uptake Value. Radiology. 2015:277(2):538-545.

Zubal, I. G., M. Early, O. Yuan, D. Jennings, K. Marek and J. P. Seibyl (2007). "Optimized, automated striatal uptake analysis applied to SPECT brain scans of Parkinson's disease patients." J Nucl Med **48**(6): 857-864.

Oliveira, F. P. and M. Castelo-Branco (2015). "Computer-aided diagnosis of Parkinson's disease based on [(123)I]FP-CIT SPECT binding potential images, using the voxels-as-features approach and support vector machines." J Neural Eng **12**(2): 026008.

Segovia, F., J. M. Gorriz, J. Ramirez, I. Alvarez, J. M. Jimenez-Hoyuela and S. J. Ortega (2012). "Improved parkinsonism diagnosis using a partial least squares based approach." Med Phys **39**(7): 4395-4403.

Palumbo, B., M. L. Fravolini, T. Buresta, F. Pompili, N. Forini, P. Nigro, P. Calabresi and N. Tambasco (2014). "Diagnostic accuracy of Parkinson disease by support vector machine (SVM) analysis of 123I-FP-CIT brain SPECT data: implications of putaminal findings and age." Medicine (Baltimore) **93**(27): e228.

Seibyl, J. P., K. Marek, K. Sheff, S. Zoghbi, R. M. Baldwin, D. S. Charney, C. H. van Dyck and R. B. Innis (1998). "Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients." J Nucl Med **39**(9): 1500-1508.

Padilla, P., J. Ramirez, J. M. Gorriz, D. Salas-Gonzalez, I. Alvarez-Illan and I. Parkinson's Progression Markers (2014). "Statistical significance in the selection of the regions of interest for Parkinson brain image processing." Stud Health Technol Inform **207**: 19-26.

Nobili, F., C. Campus, D. Arnaldi, F. De Carli, G. Cabassi, A. Brugnolo, B. Dessi, S. Morbelli, G. Sambuceti, G. Abbruzzese and G. Rodriguez (2010). "Cognitive-nigrostriatal relationships in de novo, drug-naive Parkinson's disease patients: a [I-123]FP-CIT SPECT study." Mov Disord **25**(1): 35-43.

Menendez-Gonzalez, M., F. Tavares, N. Zeidan, J. M. Salas-Pacheco and O. Arias-Carrion (2014). "Diagnoses behind patients with hard-to-classify tremor and normal DaT-SPECT: a clinical follow up study." Front Aging Neurosci **6**: 56.

Martinez-Murcia, F. J., J. M. Gorriz, J. Ramirez, M. Moreno-Caballero and M. Gomez-Rio (2014). "Parametrization of textural patterns in 123I-ioflupane imaging for the automatic detection of Parkinsonism." Med Phys **41**(1): 012502.

Kupitz, D., I. Apostolova, C. Lange, G. Ulrich, H. Amthauer, W. Brenner and R. Buchert (2014). "Global scaling for semi-quantitative analysis in FP-CIT SPECT." Nuklearmedizin **53**(6): 234-241.

Illan, I. A., J. M. Gorrz, J. Ramirez, F. Segovia, J. M. Jimenez-Hoyuela and S. J. Ortega Lozano (2012). "Automatic assistance to Parkinson's disease diagnosis in DaTSCAN SPECT imaging." Med Phys **39**(10): 5971-5980.

Brahim, A., J. Ramirez, J. M. Gorriz, L. Khedher and D. Salas-Gonzalez (2015). "Comparison between Different Intensity Normalization Methods in 123I-Ioflupane Imaging for the Automatic Detection of Parkinsonism." PLoS One **10**(6): e0130274.

Brahim, A., J. Ramirez, J. M. Gorriz, L. Khedher and D. Salas-Gonzalez (2015). "Correction: Comparison between Different Intensity Normalization Methods in 123I-Ioflupane Imaging for the Automatic Detection of Parkinsonism." PLoS One **10**(7): e0135107.

Brahim, A., J. M. Gorriz, J. Ramirez and L. Khedher (2014). "Linear intensity normalization of DaTSCAN images using Mean Square Error and a model-based clustering approach." Stud Health Technol Inform **207**: 251-260.

Kuo, P. H., H. H. Lei, R. Avery, E. A. Krupinski, A. Bauer, S. Sherman, N. McMillan, J. Seibyl and G. I. Zubal (2014). "Evaluation of an Objective Striatal Analysis Program for Determining Laterality in Uptake of 123I-Ioflupane SPECT Images: Comparison to Clinical Symptoms and to Visual Reads." J Nucl Med Technol **42**(2): 105-108.

Kuo, P. H., R. Avery, E. Krupinski, H. Lei, A. Bauer, S. Sherman, N. McMillan, J. Seibyl and G. Zubal (2013). "Receiver-operating-characteristic analysis of an automated program for analyzing striatal uptake of 123I-ioflupane SPECT images: calibration using visual reads." J Nucl Med Technol **41**(1): 26-31.

Buchert R, Kluge A, Tossici-Bolt L, Dickson J, Bronzel M, Lange C, et al. Reduction in camera-specific variability in [(123)I]FP-CIT SPECT outcome measures by image reconstruction optimized for multisite settings: impact on age-dependence of the specific binding ratio in the ENC-DAT database of healthy controls. Eur J Nucl Med Mol Imaging 2016;43(7):1323-1336.

Nobili F, Naseri M, De Carli F, Asenbaum S, Booij J, Darcourt J, et al. Automatic semi-quantification of [123I]FP-CIT SPECT scans in healthy volunteers using BasGan version 2: results from the ENC-DAT database. Eur J Nucl Med Mol Imaging 2013;40(4):565-573.

Varrone A, Dickson JC, Tossici-Bolt L, Sera T, Asenbaum S, Booij J, et al. European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. Eur J Nucl Med Mol Imaging 2013;40(2):213-27.

### **Image Certification and Interpretation**

Seibyl, J. P., A. Kupsch, J. Booij, D. G. Grosset, D. C. Costa, R. A. Hauser, J. Darcourt, N. Bajaj, Z. Walker, K. Marek, I. McKeith, J. T. O'Brien, K. Tatsch, E. Tolosa, R. A. Dierckx and I. D. Grachev (2014). "Individual-Reader Diagnostic Performance and Between-Reader Agreement in Assessment of Subjects with Parkinsonian Syndrome or Dementia Using 123I-Ioflupane Injection (DaTscan) Imaging." J Nucl Med **55**(8): 1288-1296.

Seibyl, J., K. Marek and I. G. Zubal (2010). "The role of the core imaging laboratory in multicenter trials." Semin Nucl Med **40**(5): 338-346.

### **MISC**

Mozley PD, Schneider JS, Acton PD, Barraclough ED, Stern MB, Leopold NA, Plössl K, Siderowf A, Li PY, Gollomp SM, Alavi A, Kung HF. Binding of [Tc-99m]TRODAT-1 to dopamine transporters in patients with Parkinson’s disease and healthy volunteers. J Nucl Med 2000; 41:584-589.

Lynch D, Mozley PD, Sokal S, Maas NMC, Balcer LJ, Siderowf AD. Lack of effect of polymorphisms in dopamine metabolism related genes on imaging of TRODAT-1 in striatum of asymptomatic volunteers and patients with Parkinson's disease. Movement Disorders 2003; 18(7):804-812.

Mozley PD, Stubbs JB, Kim H-J, McElgin W, Kung HF: Dosimetry of an iodine-123-labeled tropane to image dopamine transporters. J Nucl Med 1996; 37:151-159.

Mozley PD, Stubbs JB, Plössl K, Dressl SH, Barraclough ED, Alavi A, Araujo LI, Kung HF. The biodistribution and dosimetry of a [Tc-99m] labeled tropane for imaging dopamine transporters. J Nucl Med 1998; 39:1960-1967.

Mozley PD, Acton PD, Barraclough ED, Plössl K, Gur RC, Mathur A, Alavi A, Saffer J, Kung HF. Effects of age on dopamine transporters in healthy humans. J Nucl Med 1999; 40:1812:1817.

Seibyl, J. P., M. Laruelle, C. H. van Dyck, E. Wallace, R. M. Baldwin, S. Zoghbi, Y. Zea-Ponce, J. L. Neumeyer, D. S. Charney, P. B. Hoffer and R. B. Innis (1996). "Reproducibility of iodine-123-beta-CIT SPECT brain measurement of dopamine transporters." J Nucl Med **37**(2): 222-228.

Seibyl, J. P., K. Marek, K. Sheff, R. M. Baldwin, S. Zoghbi, Y. Zea-Ponce, D. S. Charney, C. H. van Dyck, P. B. Hoffer and R. B. Innis (1997). "Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients." J Nucl Med **38**(9): 1453-1459.

Ravina, B., D. Eidelberg, J. E. Ahlskog, R. L. Albin, D. J. Brooks, M. Carbon, V. Dhawan, A. Feigin, S. Fahn, M. Guttman, K. Gwinn-Hardy, H. McFarland, R. Innis, R. G. Katz, K. Kieburtz, S. J. Kish, N. Lange, J. W. Langston, K. Marek, L. Morin, C. Moy, D. Murphy, W. H. Oertel, G. Oliver, Y. Palesch, W. Powers, J. Seibyl, K. D. Sethi, C. W. Shults, P. Sheehy, A. J. Stoessl and R. Holloway (2005). "The role of radiotracer imaging in Parkinson disease." Neurology **64**(2): 208-215.

Parkinson Progression Marker, I. (2011). "The Parkinson Progression Marker Initiative (PPMI)." Prog Neurobiol **95**(4): 629-635.

Marek, K., J. Seibyl, S. Eberly, D. Oakes, I. Shoulson, A. E. Lang, C. Hyson, D. Jennings and P. I. Parkinson Study Group (2014). "Longitudinal follow-up of SWEDD subjects in the PRECEPT Study." Neurology **82**(20): 1791-1797.

Jennings, D., A. Siderowf, M. Stern, J. Seibyl, S. Eberly, D. Oakes, K. Marek and P. Investigators (2014). "Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study." Neurology **83**(19): 1739-1746.

Jacobsen, L. K., J. K. Staley, S. S. Zoghbi, J. P. Seibyl, T. R. Kosten, R. B. Innis and J. Gelernter (2000). "Prediction of dopamine transporter binding availability by genotype: a preliminary report." Am J Psychiatry **157**(10): 1700-1703.

Isaias, I. U., M. Canesi, R. Benti, P. Gerundini, R. Cilia, G. Pezzoli and A. Antonini (2008). "Striatal dopamine transporter abnormalities in patients with essential tremor." Nucl Med Commun **29**(4): 349-353.

Isaias, I. U., R. Benti, S. Goldwurm, M. Zini, R. Cilia, P. Gerundini, A. Di Fonzo, V. Bonifati, G. Pezzoli and A. Antonini (2006). "Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation." Mov Disord **21**(8): 1144-1147.

Innis, R. B., K. L. Marek, K. Sheff, S. Zoghbi, J. Castronuovo, A. Feigin and J. P. Seibyl (1999). "Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT." Mov Disord **14**(3): 436-442.

Best, S. E., P. M. Sarrel, R. T. Malison, M. Laruelle, S. S. Zoghbi, R. M. Baldwin, J. P. Seibyl, R. B. Innis and C. H. van Dyck (2005). "Striatal dopamine transporter availability with [123I]beta-CIT SPECT is unrelated to gender or menstrual cycle." Psychopharmacology (Berl) **183**(2): 181-189.

Bajaj, N., R. A. Hauser, J. Seibyl, A. Kupsch, M. Plotkin, C. Chen and I. D. Grachev (2014). "Association between Hoehn and Yahr, Mini-Mental State Examination, age, and clinical syndrome predominance and diagnostic effectiveness of ioflupane I 123 injection (DaTSCAN) in subjects with clinically uncertain parkinsonian syndromes." Alzheimers Res Ther **6**(5-8): 67.

Bajaj, N., R. A. Hauser and I. D. Grachev (2013). "Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes." J Neurol Neurosurg Psychiatry **84**(11): 1288-1295.

Antonini, A., R. Benti, R. De Notaris, S. Tesei, A. Zecchinelli, G. Sacilotto, N. Meucci, M. Canesi, C. Mariani, G. Pezzoli and P. Gerundini (2003). "123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy." Neurol Sci **24**(3): 149-150.

Cheng, G. and J. F. Morley (2014). "Complete and readily reversible blocking of striatal DaTscan binding by methylphenidate." Clin Nucl Med **39**(2): 211-213.

Thomsen G, Knudsen GM, Jensen PS, Ziebell M, Holst KK, Asenbaum S, et al. No difference in striatal dopamine transporter availability between active smokers, ex-smokers and non-smokers using [123I]FP-CIT (DaTSCAN) and SPECT. EJNMMI Res 2013;3(1):39.

Iida H, Nakagawara J, Hayashida K, Fukushima K, Watabe H, Koshino K, et al. Multicenter evaluation of a standardized protocol for rest and acetazolamide cerebral blood flow assessment using a quantitative SPECT reconstruction program and split-dose 123I-iodoamphetamine. J Nucl Med 2010;51(10):1624-31.

# Appendices

## Appendix A: Acknowledgements and Attributions

The QIBA SPECT Committee followed the profile document template of 05 November 2016 proffered by the QIBA something committee, Kevin O’Donnell, principal editor, to whom we are grateful for continuous guidance.

The SPECT Committee is grateful to the pioneering work of the CT Volumetry Committee, and particularly to the FDG PET Committee, for extensive guidance on how to create this profile.

This Profile benefited extensively from the Japanese Quantitative Imaging Biomarker Alliance (QIBA-Japan). Responses to their many thoughtful, constructive, and collegial suggestions can be found throughout the document.

This work was made possible by the professional staff of the Radiological Society of North America reporting up through Fiona Miller and Linda Bresolin, PhD. Julie Lisiecki usually took the lead, and was often backed up by Joseph Koudelik and Susan Weinmann, among others.

The following people, listed in alphabetical order, contributed to the development and publication of this profile:

|  |  |
| --- | --- |
| **QIBA SPECT Biomarker Committee Participants** |   |
| Patrick Cella, MSc  | GE Healthcare |
| Yuni Dewaraja, PhD (Co-Chair) | University of Michigan |
| John Dickson, PhD (Task Force Co-Chair) | University College London (UK) |
| Rachid Fahmi, MSc, PhD | Siemens |
| Eric Frey, PhD  | Johns Hopkins |
| Hidehiro Iida, DSc, PhD  | National Cerebral & Cardiovascular Center - Research Institute (Osaka, Japan) |
| Abhinav K. Jha, PhD  | Johns Hopkins |
| S. Cheenu Kappadath, PhD | University of Texas MD Anderson Cancer Center |
| Paul E. Kinahan, PhD, FIEEE | University of Washington |
| Gregory Klein, PhD  | BioClinica, Inc. |
| Richard LaForest, PhD  | Mallinckrodt Institute of Radiology, Washington University in St. Louis |
| Michael Lassmann, PhD | University of Würzburg (Germany) |
| Manuela Matesan, MD, PhD | University of Washington |
| Robert S. Miyaoka, PhD (Task Force Co-Chair) | University of Washington |
| P. David Mozley, MD (Co-Chair) | Endocyte, Inc. |
| Nancy Obuchowski, PhD | Cleveland Clinic Foundation |
| Amy Perkins, PhD | Philips |
| Eric S. Perlman, MD  | Perlman Advisory Group, LLC |
| John Seibyl, MD, Co-Chair | Molecular Neuroimaging Inc., a division of inviCRO |
| Anne M. Smith, PhD | Siemens |
| John Sunderland, PhD | University of Iowa |
| Pierre Tervé, MS | Keosys (France) |
| Benjamin M. W. Tsui, PhD | Johns Hopkins |
| Richard L. Wahl, MD, FACR | Mallinckrodt Institute of Radiology, Washington University in St. Louis |
| Johannes Zeintl, PhD | Siemens |
| Brian Zimmerman, PhD (Task Force Co-Chair) | National Institute of Standards and Technology (NIST) |